IN2012DN04853A - - Google Patents

Download PDF

Info

Publication number
IN2012DN04853A
IN2012DN04853A IN4853DEN2012A IN2012DN04853A IN 2012DN04853 A IN2012DN04853 A IN 2012DN04853A IN 4853DEN2012 A IN4853DEN2012 A IN 4853DEN2012A IN 2012DN04853 A IN2012DN04853 A IN 2012DN04853A
Authority
IN
India
Prior art keywords
diastereoisomer
tautomer
enantiomer
inhibitor
ester
Prior art date
Application number
Other languages
English (en)
Inventor
S Tsantrizos Youla
Chabot Catherine
Beaulieu Pierre
Brochu Christian
Poirier Martin
A Stammers Timothy
Thavonkeham Bounkham
Rancourt Jean
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34886250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN04853(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IN2012DN04853A publication Critical patent/IN2012DN04853A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IN4853DEN2012 2004-02-20 2005-02-18 IN2012DN04853A (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54621304P 2004-02-20 2004-02-20
PCT/CA2005/000208 WO2005080388A1 (en) 2004-02-20 2005-02-18 Viral polymerase inhibitors

Publications (1)

Publication Number Publication Date
IN2012DN04853A true IN2012DN04853A (sr) 2015-09-25

Family

ID=34886250

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4853DEN2012 IN2012DN04853A (sr) 2004-02-20 2005-02-18

Country Status (30)

Country Link
US (3) US7582770B2 (sr)
EP (2) EP1718608B1 (sr)
JP (4) JP4648333B2 (sr)
KR (2) KR101320907B1 (sr)
CN (6) CN103304541A (sr)
AR (2) AR047706A1 (sr)
AU (1) AU2005215829C1 (sr)
BR (1) BRPI0507861A (sr)
CA (1) CA2553879C (sr)
DK (1) DK1718608T3 (sr)
EA (3) EA201301284A1 (sr)
EC (1) ECSP066780A (sr)
ES (1) ES2431314T3 (sr)
HR (1) HRP20130971T1 (sr)
IL (2) IL177537A (sr)
IN (1) IN2012DN04853A (sr)
MY (1) MY144718A (sr)
NO (1) NO20064004L (sr)
NZ (1) NZ549079A (sr)
PE (1) PE20051141A1 (sr)
PL (1) PL1718608T3 (sr)
PT (1) PT1718608E (sr)
RS (1) RS52931B (sr)
SG (2) SG150511A1 (sr)
SI (1) SI1718608T1 (sr)
TW (2) TWI368507B (sr)
UA (2) UA86962C2 (sr)
UY (1) UY28758A1 (sr)
WO (1) WO2005080388A1 (sr)
ZA (1) ZA200605151B (sr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298749B6 (cs) 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7223785B2 (en) * 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) * 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
PE20050374A1 (es) 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
UY28758A1 (es) * 2004-02-20 2005-09-30 Boehringer Ingelheim Int Inhibidores de polimerasa viral
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
MY141025A (en) 2004-10-29 2010-02-25 Vertex Pharma Dose forms
CA2597680A1 (en) * 2005-02-11 2006-08-17 Boehringer Ingelheim International Gmbh Process for preparing 2,3-disubstituted indoles
JP5015154B2 (ja) * 2005-08-12 2012-08-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼインヒビター
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CA2643688A1 (en) 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
WO2007109080A2 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
JP2010500978A (ja) 2006-08-17 2010-01-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼインヒビター
CA2672290A1 (en) * 2007-01-15 2008-07-24 The United States Of America, As Represented By The Secretary Of The Arm Y, On Behalf Of The U.S. Army Research Institute Of Infectious Diseases Antiviral compounds and methods of using thereof
WO2008106058A2 (en) 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
GEP20125645B (en) 2007-02-27 2012-09-25 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
ES2381410T3 (es) 2007-05-04 2012-05-28 Vertex Pharmceuticals Incorporated Terapia de combinación paa el tratamiento de infecciones por VHC
JP2010533699A (ja) 2007-07-17 2010-10-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Ｃ型肝炎感染症の治療のための大環状インドール誘導体
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
WO2009032198A1 (en) 2007-08-30 2009-03-12 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
CA2708150A1 (en) 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Fluorinated tripeptide hcv serine protease inhibitors
WO2009076747A1 (en) 2007-12-19 2009-06-25 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
WO2010018131A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
WO2010018134A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Novel adenine derivatives
EP2337583A1 (en) * 2008-09-17 2011-06-29 Boehringer Ingelheim International GmbH Combination of hcv ns3 protease inhibitor with interferon and ribavirin
JP2012051803A (ja) * 2008-12-25 2012-03-15 Kyorin Pharmaceutical Co Ltd 環状アミノ安息香酸エステル誘導体の製造方法
WO2010080874A1 (en) 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
EP2396028A2 (en) 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
US8410144B2 (en) 2009-03-31 2013-04-02 Arqule, Inc. Substituted indolo-pyridinone compounds
CN102458444A (zh) 2009-05-13 2012-05-16 英安塔制药有限公司 用作丙型肝炎病毒抑制剂的大环化合物
EA020031B1 (ru) * 2009-06-11 2014-08-29 Эббви Бахамаз Лтд. Противовирусные соединения
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
WO2010149359A1 (en) * 2009-06-26 2010-12-29 Lonza Ltd Process and intermediates for the preparation of benzimidazolecarboxylic acids
EP2454254A2 (en) * 2009-07-16 2012-05-23 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
BR112012010110A2 (pt) 2009-10-30 2019-09-24 Boehringer Ingelheim Int regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina
CN102844030A (zh) 2010-01-29 2012-12-26 沃泰克斯药物股份有限公司 用于治疗丙型肝炎病毒感染的疗法
ES2525826T3 (es) 2010-02-10 2014-12-30 Glaxosmithkline Llc Maleato de 6-amino-2-{[(1s)-1-metilbutil]-oxi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8H-purin-8-ona
WO2011098451A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
EP2593105A1 (en) 2010-07-14 2013-05-22 Vertex Pharmaceuticals Incorporated Palatable pharmaceutical composition comprising vx-950
HUE028384T2 (en) 2010-09-21 2016-12-28 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
CA2813179A1 (en) * 2010-09-30 2012-04-05 Boehringer Ingelheim International Gmbh Solid state forms of a potent hcv inhibitor
AP2013006734A0 (en) * 2010-09-30 2013-02-28 Boehringer Ingelheim Int Combination therapy for treating HCV infection
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
US20130195797A1 (en) 2012-01-31 2013-08-01 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
WO2013147750A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
WO2013147749A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient subgenotype populations
US20130261134A1 (en) * 2012-03-30 2013-10-03 Boehringer Ingelheim International Gmbh Mesylate salt forms of a potent hcv inhibitor
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
CN103408430B (zh) * 2013-08-30 2014-09-17 南京理工大学 一种2-甲基-4-硝基苯甲酸的合成方法
WO2015124591A1 (en) 2014-02-20 2015-08-27 Glaxosmithkline Intellectual Property (No.2) Limited Pyrrolo[3,2] pyrimidine derivatives as inducers of human interferon
CN104130143B (zh) * 2014-08-06 2017-02-15 江苏鼎龙科技有限公司 3‑甲氨基‑4‑硝基苯氧乙醇的制备方法
MX2017006302A (es) 2014-11-13 2018-02-16 Glaxosmithkline Biologicals Sa Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
JP6411676B2 (ja) 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｓｔｉｎｇの調節因子としての環状プリンジヌクレオチド
CN113549110B (zh) 2016-04-07 2024-08-16 葛兰素史密斯克莱知识产权发展有限公司 用作蛋白质调节剂的杂环酰胺
KR20180132783A (ko) 2016-04-07 2018-12-12 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 단백질 조절제로서 유용한 헤테로사이클릭 아미드
CN105884627A (zh) * 2016-04-22 2016-08-24 成都东电艾尔科技有限公司 一种氧烯洛尔药物中间体邻氨基苯酚的合成方法
EP3241830A1 (de) 2016-05-04 2017-11-08 Bayer CropScience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
EP3497102B1 (de) 2016-08-15 2022-12-07 Bayer CropScience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
JOP20190024A1 (ar) * 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
JOP20190188A1 (ar) * 2017-02-01 2019-08-01 Rempex Pharmaceuticals Inc جهاز وعملية تدفق مستمرة لإنتاج مشتق حمض بورونيك
WO2019069270A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited GENERATOR STIMULATOR MODULATORS (STING) INTERFERON
EP3692033A1 (en) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
CN111741958A (zh) 2018-02-21 2020-10-02 拜耳公司 作为害虫防治剂的稠合双环杂环衍生物
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
JP2022533390A (ja) 2019-05-16 2022-07-22 スティングセラ インコーポレイテッド オキソアクリジニル酢酸誘導体および使用方法
WO2020232378A1 (en) 2019-05-16 2020-11-19 Silicon Swat, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021119753A1 (en) 2019-12-18 2021-06-24 Ctxt Pty Limited Compounds
US20230357125A1 (en) * 2022-05-06 2023-11-09 AMPAC Fine Chemicals Process for Catalytic Reduction of Nitro Compounds to Amines
CN115304584B (zh) * 2022-07-25 2023-05-26 云南大学 3-硫甲基-(5’-芳基-1h-吡唑)-吲哚类化合物及其制备方法和用途

Family Cites Families (215)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1094903A (en) 1964-03-26 1967-12-13 Smith Kline French Lab Improvements in or relating to nitrofuran derivatives
FR1604809A (en) 1965-11-26 1972-04-17 Thiazolyl benzimidazoles - animal feed additives
GB1186504A (en) 1966-10-15 1970-04-02 Fisons Pest Control Ltd Substituted Heterocyclic Compounds
NL6917115A (sr) 1968-11-22 1970-05-26
US3565912A (en) 1969-01-27 1971-02-23 Upjohn Co 5-lower-alkanoyl-2,3-bis(p-methoxyphenyl)indoles
DE2346316C2 (de) 1973-09-14 1985-02-14 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von 2-Furylbenzimidazolen
GB1509527A (en) 1974-06-05 1978-05-04 Ici Ltd 1-(aryl-or heteroaryl)oxy-3-(substituted-amino)propan-2-ol derivatives processes for their manufacture and pharmaceutical compositions containing them
FR2291749A1 (fr) 1974-11-20 1976-06-18 Delalande Sa Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique
US4003908A (en) 1976-03-11 1977-01-18 E. R. Squibb & Sons, Inc. Derivatives of imidazo(4,5-b)pyridines
CH632628B (de) 1976-07-26 Ciba Geigy Ag Verfahren zur herstellung von benzofuranyl-benzimidazolen und deren verwendung als optische aufheller.
DE2641060A1 (de) 1976-09-11 1978-03-16 Hoechst Ag Beta-lactamverbindungen und verfahren zu ihrer herstellung
US4264325A (en) 1977-02-22 1981-04-28 Ciba-Geigy Corporation Phenyl-benzimidazolyl-furanes for optical brightening of organic materials
DE2720111A1 (de) 1977-05-05 1978-11-16 Agfa Gevaert Ag Korrosionsschutzmittel fuer zweibad-stabilisatorbaeder
EP0010063B1 (de) 1978-10-04 1982-12-29 Ciba-Geigy Ag Verfahren zur Herstellung von Furanyl-benzazolen
ZA795239B (en) 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
DE2852531A1 (de) 1978-12-05 1980-06-19 Bayer Ag Benzofuranyl-benzimidazole
DE2853765A1 (de) 1978-12-13 1980-06-26 Bayer Ag Verfahren zur herstellung von benzimidazolylbenzofuranen
DE2904829A1 (de) 1979-02-08 1980-08-14 Bayer Ag Verfahren zur herstellung von benzimidazolylbenzofuran
EP0029003B1 (de) 1979-11-01 1984-12-05 Ciba-Geigy Ag Salze kationischer Aufheller, deren Herstellung und deren Verwendung auf organischen Materialien sowie deren konzentrierte wässrige Lösungen
GR75101B (sr) 1980-10-23 1984-07-13 Pfizer
GB8707798D0 (en) 1987-04-01 1987-05-07 Ici Plc Recovery of metals
ZA825413B (en) 1981-08-26 1983-06-29 Pfizer Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them
GB2118552A (en) 1982-04-15 1983-11-02 Pfizer Ltd Thromboxane synthetase inhibitors
JPS60149502A (ja) 1984-01-12 1985-08-07 Kuraray Co Ltd インド−ル系農園芸用殺菌剤
LU85544A1 (fr) 1984-09-19 1986-04-03 Cird Derives heterocycliques aromatiques,leur procede de preparation et leur application dans les domaines therapeutique et cosmetique
DE3522230A1 (de) 1985-06-21 1987-01-02 Thomae Gmbh Dr K Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB8707051D0 (en) 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
GB8609175D0 (en) 1986-04-15 1986-05-21 Ici America Inc Heterocyclic carboxamides
US4859684A (en) 1986-09-15 1989-08-22 Janssen Pharmaceutica N.V. (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use thereof in treating androgen dependent disorders
CA1322005C (en) 1987-11-25 1993-09-07 Robert N. Young Benzoheterazoles
JP2700475B2 (ja) 1988-07-30 1998-01-21 コニカ株式会社 非線形光学材料および非線形光学素子
JPH03157646A (ja) 1989-11-15 1991-07-05 Konica Corp ハロゲン化銀写真感光材料
JPH03219232A (ja) 1990-01-24 1991-09-26 Konica Corp 分光増感されたハロゲン化銀写真感光材料
CA2077897A1 (en) 1990-04-13 1991-10-14 Robert G. Franz Substituted benzimidazoles
JP2909645B2 (ja) 1990-05-28 1999-06-23 コニカ株式会社 ハロゲン化銀カラー写真感光材料
US5110494A (en) 1990-08-24 1992-05-05 Man-Gill Chemical Company Alkaline cleaner and process for reducing stain on aluminum surfaces
AU656551B2 (en) 1990-12-14 1995-02-09 Smithkline Beecham Corporation Angiotensin II receptor blocking compositions
US5527819A (en) 1991-09-06 1996-06-18 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9121463D0 (en) 1991-10-10 1991-11-27 Smithkline Beecham Corp Medicament
GB9122590D0 (en) 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
JPH05165163A (ja) 1991-12-11 1993-06-29 Konica Corp 色素画像形成方法
JP3013124B2 (ja) 1991-12-26 2000-02-28 コニカ株式会社 カラー画像形成方法
US5216003A (en) 1992-01-02 1993-06-01 G. D. Searle & Co. Diacid-containing benzimidazole compounds for treatment of neurotoxic injury
US5314796A (en) 1992-04-02 1994-05-24 Konica Corporation Silver halide color photographic light sensitive material
US5387600A (en) 1992-07-30 1995-02-07 Fuji Photo Film Co., Ltd. Treating arteriosclerosis using benzimidazole compositions
DE4237557A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
DE4237617A1 (de) 1992-11-06 1994-05-11 Bayer Ag Verwendung von substituierten Benzimidazolen
BR9307570A (pt) 1992-12-02 1999-05-25 Pfizer Diéteres de catecol como inibidores seletivos de pdeiv
JP3213426B2 (ja) 1993-02-19 2001-10-02 エーザイ株式会社 ６，７−ジヒドロ−５Ｈ−シクロペンタ〔ｄ〕ピリミジン誘導体
DE69434016T2 (de) 1993-03-04 2005-02-10 Fuji Photo Film Co., Ltd., Minami-Ashigara Photographisches Silberhalogenidmaterial
DE4309969A1 (de) 1993-03-26 1994-09-29 Bayer Ag Substituierte heteroanellierte Imidazole
US6169107B1 (en) 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
JP3156444B2 (ja) 1993-06-02 2001-04-16 松下電器産業株式会社 短波長レーザ光源およびその製造方法
DE4330959A1 (de) 1993-09-09 1995-03-16 Schering Ag Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
ES2157268T5 (es) 1994-02-24 2004-12-01 SYMRISE GMBH & CO KG Preparados cosmeticos y dermatologicos que contienen acidos fenilen-1,4-bisbencimidazolsulfonicos.
CA2124169A1 (en) 1994-05-24 1995-11-25 Richard Mcculloch Keenan Chemical compounds
WO1995032949A1 (en) 1994-05-27 1995-12-07 James Black Foundation Limited Gastrin and cck antagonists
PT801059E (pt) 1994-11-29 2001-10-30 Dainippon Pharmaceutical Co Derivado indol
EP0717143A1 (de) 1994-12-16 1996-06-19 Lignozym GmbH Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung
DE19507913C2 (de) 1995-03-07 1998-04-16 Agfa Gevaert Ag Farbfotografisches Silberhalogenidmaterial
KR100430059B1 (ko) 1995-04-10 2004-09-24 후지사와 야꾸힝 고교 가부시키가이샤 cGMP-PDE억제제로서의인돌유도체
US6444694B1 (en) 1995-06-06 2002-09-03 Wyeth Styryl benzimidazole derivatives
JP3544245B2 (ja) 1995-06-09 2004-07-21 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料の処理方法
WO1997006141A1 (en) 1995-08-04 1997-02-20 Otsuka Kagaku Kabushiki Kaisha Indole-2-carboxylic ester derivatives and agricultural and horticultural bacteriocides containing the same as the active ingredient
CZ292632B6 (cs) 1995-10-05 2003-11-12 Kyoto Pharmaceutical Industries, Ltd. Indolinový, indolový nebo tetrahydrochinolinový derivát a farmaceutický přípravek s jeho obsahem
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
JPH09124632A (ja) 1995-10-31 1997-05-13 Sankyo Co Ltd ベンゾヘテロ環誘導体
CA2241186C (en) 1995-12-28 2006-02-14 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
GB9610811D0 (en) 1996-05-23 1996-07-31 Pharmacia Spa Combinatorial solid phase synthesis of a library of indole derivatives
JP4373497B2 (ja) 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
GB9614347D0 (en) 1996-07-09 1996-09-04 Smithkline Beecham Spa Novel compounds
AUPO118896A0 (en) 1996-07-23 1996-08-15 Fujisawa Pharmaceutical Co., Ltd. New use
TR199900389T2 (xx) 1996-08-28 2000-06-21 Pfizer Inc. �kame edilmi� 6,5-hetero-bisiklik t�revleri.
JPH10114654A (ja) 1996-10-09 1998-05-06 Fujisawa Pharmaceut Co Ltd 新規用途
EP0949259B1 (en) 1996-12-26 2001-06-20 Nikken Chemicals Company, Limited N-hydroxyurea derivatives and medicinal compositions containing the same
JPH10204059A (ja) 1997-01-22 1998-08-04 Ono Pharmaceut Co Ltd フェニルスルホンアミド誘導体
JP4495257B2 (ja) 1997-02-19 2010-06-30 バーレツクス ラボラトリーズ インコーポレーテツド Ｎｏｓ抑制剤としてのｎ−複素環誘導体
WO1998037069A1 (en) 1997-02-20 1998-08-27 Shionogi & Co., Ltd. Indole dicarboxylic acid derivatives
EP1012180B1 (en) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
DE69829381T2 (de) 1997-08-11 2006-04-13 Boehringer Ingelheim (Canada) Ltd., Laval Hepatitis c inhibitor peptide
US5932743A (en) 1997-08-21 1999-08-03 American Home Products Corporation Methods for the solid phase synthesis of substituted indole compounds
DE19753522A1 (de) 1997-12-03 1999-06-10 Boehringer Ingelheim Pharma Substituierte Indole, ihre Herstellung und ihre Verwendung als Arzneimittel
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
JPH11177218A (ja) 1997-12-12 1999-07-02 Tamura Kaken Co Ltd 電子回路用金属面具備部品及びその表面保護剤
WO1999061013A2 (en) 1998-05-22 1999-12-02 Avanir Pharmaceuticals COMPOUNDS HAVING IgE AFFECTING PROPERTIES
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
DK1087952T3 (da) 1998-06-18 2004-10-04 Novartis Ag Banzazolforbindelser samt deres anvendelse
US7223879B2 (en) 1998-07-10 2007-05-29 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US6445525B1 (en) * 1998-07-16 2002-09-03 Seagate Technology Llc Disc drive performance by reducing areal data storage density
ATE298317T1 (de) 1998-07-27 2005-07-15 Angeletti P Ist Richerche Bio Diketosäure-derivate als hemmstoffe von polymerasen
AU5227999A (en) 1998-07-27 2000-02-21 Abbott Laboratories Substituted oxazolines as antiproliferative agents
US6228868B1 (en) 1998-07-27 2001-05-08 Abbott Laboratories Oxazoline antiproliferative agents
GB9816654D0 (en) 1998-07-30 1998-09-30 Zeneca Ltd Chemical compounds
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
ID27787A (id) 1998-08-21 2001-04-26 Viro Pharma Inc Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan
US6440985B1 (en) 1998-09-04 2002-08-27 Viropharma Incorporated Methods for treating viral infections
WO2000018231A1 (en) 1998-09-25 2000-04-06 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
ES2180338T3 (es) 1998-11-12 2003-02-01 Neurocrine Biosciences Inc Antagonistas del receptor de crf y metodos relacionados.
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
US6358992B1 (en) 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
US6869950B1 (en) 1998-12-24 2005-03-22 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
EP1175419B1 (en) 1999-04-02 2003-05-28 Bristol-Myers Squibb Pharma Company Aryl sulfonyls as factor xa inhibitors
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6478874B1 (en) 1999-08-06 2002-11-12 Engelhard Corporation System for catalytic coating of a substrate
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
JP2001122855A (ja) 1999-10-27 2001-05-08 Japan Tobacco Inc インドール化合物及びその医薬用途
DE69907961T2 (de) 1999-10-28 2004-03-11 Eoc Surfactants Nv Verfahren zur herstellung fliessfähiger, konzentrierter betainlösungen
AU1262001A (en) 1999-11-04 2001-05-14 Biochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
EP1990343B1 (en) 1999-12-24 2012-04-04 Aventis Pharma Limited Azaindoles
EP1162196A4 (en) * 1999-12-27 2003-04-16 Japan Tobacco Inc COMPOUNDS WITH JOINED CYCLES AND THEIR USE AS MEDICAMENTS
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
EA004673B1 (ru) 1999-12-28 2004-06-24 Пфайзер Продактс Инк. Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний
GB0003397D0 (en) 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
CN1427722A (zh) 2000-02-18 2003-07-02 希拉生物化学股份有限公司 用核苷类似物治疗或预防黄病毒感染的方法
AU2001253206A1 (en) 2000-04-05 2001-10-23 Tularik, Inc. Ns5b hcv polymerase inhibitors
US6713502B2 (en) 2000-05-05 2004-03-30 Smithkline Beecham Corporation Anti-infectives
WO2001085172A1 (en) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
PY0111577A (es) 2000-05-23 2017-01-02 Idenix Cayman Ltd Métodos y composiciones para el tratamiento del virus de la hepatitis c
KR100372218B1 (ko) 2000-06-29 2003-02-14 바이오인포메틱스 주식회사 유기산을 생산하는 균주 및 이를 이용한 유기산의 생산방법
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
AU2001282528A1 (en) 2000-09-01 2002-03-22 Shionogi And Co., Ltd. Compounds having anti-hepatitis c virus effect
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
CA2429359A1 (en) 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
CN1482914A (zh) 2000-12-26 2004-03-17 三菱制药株式会社 丙型肝炎治疗剂
SI1355916T1 (sl) 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
GB0102109D0 (en) 2001-01-26 2001-03-14 Syngenta Ltd Chemical process
WO2002069903A2 (en) 2001-03-06 2002-09-12 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
HUP0400039A3 (en) 2001-03-08 2004-10-28 Boehringer Ingelheim Ca Ltd Hcv polymerase inhibitor assay
KR100798579B1 (ko) 2001-03-31 2008-01-28 동화약품공업주식회사 신규의 메톡시-1,3,5-트리아진 유도체 및 그를 포함하는약학적 조성물
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
GB0112617D0 (en) 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
CA2449999C (en) 2001-06-11 2012-07-31 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
AU2002344854B2 (en) 2001-06-11 2008-11-06 Vertex Pharmaceuticals (Canada) Incorporated Thiophene derivatives as antiviral agents for flavivirus infection
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
EP1404694A1 (en) 2001-06-21 2004-04-07 Glaxo Group Limited Nucleoside compounds in hcv
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
KR100713137B1 (ko) 2001-06-28 2007-05-02 동화약품공업주식회사 신규의 2,4-디플루오로벤즈아미드 유도체
WO2003007945A1 (en) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7294457B2 (en) 2001-08-07 2007-11-13 Boehringer Ingelheim (Canada) Ltd. Direct binding assay for identifying inhibitors of HCV polymerase
WO2003018555A1 (en) 2001-08-22 2003-03-06 Ciba Speciality Chemicals Holding Inc. Process for the preparation of indole derivatives
WO2003020222A2 (en) 2001-09-04 2003-03-13 Merck & Co., Inc. PYRROLO[2,3-d]PYRIMIDINES FOR INHIBITING RNA-DEPENDENT RNA VIRAL POLYMERASE
US20030134853A1 (en) 2001-09-26 2003-07-17 Priestley Eldon Scott Compounds useful for treating hepatitis C virus
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
EP1438054A4 (en) 2001-09-28 2006-07-26 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION
AU2002359320A1 (en) 2001-10-29 2003-05-12 Smithkline Beecham Corporation Novel anit-infectives
AU2002365198A1 (en) 2001-10-30 2003-07-30 Smithkline Beecham Corporation Novel anti-infectives
JP2005515172A (ja) 2001-11-02 2005-05-26 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としての４−（６−員）−ヘテロアリールアシルピロリジン誘導体
JP2005511572A (ja) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としてのアシルジヒドロピロール誘導体
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
JP2005511573A (ja) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としての４−（５−員）−ヘテロアリールアシルピロリジン誘導体
WO2003042265A1 (fr) 2001-11-13 2003-05-22 Toray Industries, Inc. Polymere et lentilles ophthalmologiques realisees a l'aide de ce polymere
US20050033051A1 (en) 2001-11-14 2005-02-10 Babu Yarlagadda S Nucleosides preparation thereof and use as inhibitors of rna viral polymerases
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US6936629B2 (en) 2001-12-21 2005-08-30 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
EP1572705A2 (en) 2002-01-17 2005-09-14 Ribapharm, Inc. Sugar modified nucleosides as viral replication inhibitors
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
WO2003061385A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. Tricyclic nucleoside library compounds, synthesis, and use as antiviral agents
GB0201179D0 (en) 2002-01-18 2002-03-06 Angeletti P Ist Richerche Bio Therapeutic agents
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
WO2003082848A1 (en) 2002-04-01 2003-10-09 Pfizer Inc. Pyranon and pyrandion inhibitors of hepatitis c virus rna-dependent rna polymerase
KR100516434B1 (ko) 2002-04-04 2005-09-22 (주) 비엔씨바이오팜 6-(4-치환된-아닐리노)피리미딘 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
AU2003237088A1 (en) 2002-04-23 2003-11-10 Viropharma Incorporated Compounds, compositions and methods for treating or preventing viral infections and associated diseases
KR20050006221A (ko) 2002-05-06 2005-01-15 제네랩스 테크놀로지스, 인코포레이티드 Ｃ형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
GB0211418D0 (en) 2002-05-17 2002-06-26 Glaxo Group Ltd Compounds
WO2004032827A2 (en) 2002-05-20 2004-04-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US6878722B2 (en) 2002-05-20 2005-04-12 Bristol-Myers Squibb Company Substituted cycloalkyl P1′ hepatitis C virus inhibitors
EP1506000B9 (en) 2002-05-20 2011-08-31 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
TW200400818A (en) 2002-05-21 2004-01-16 Wyeth Corp Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus
TW200400963A (en) 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
WO2003099801A1 (en) 2002-05-24 2003-12-04 Smithkline Beecham Corporation Novel anti-infectives
EP1511751B1 (en) 2002-06-04 2008-03-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidine compounds as antiviral agents
CA2488842A1 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. Carbocyclic nucleoside analogs as rna-antivirals
WO2004000242A1 (en) 2002-06-25 2003-12-31 Cosmeceutic Solutions Pty Ltd Topical cosmetic compositions
AU2003269892A1 (en) 2002-06-27 2004-01-19 Isis Pharmaceuticals, Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
EP1525209B1 (en) 2002-06-28 2017-11-15 Idenix Pharmaceuticals LLC 1'-, 2'- and 3' -modified nucleoside derivatives for treating flaviviridae infections
PT1523489E (pt) 2002-06-28 2014-06-24 Centre Nat Rech Scient Profármacos de nucleósido modificado em 2' e 3' para tratamento de infecções por flaviridae
BR0305259A (pt) 2002-07-01 2004-10-05 Upjohn Co Inibidores de hcv ns5b polimerase
BR0305426A (pt) 2002-07-01 2004-08-24 Upjohn Co Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
AU2003269902A1 (en) 2002-07-16 2004-02-02 Isis Pharmaceuticals, Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
AU2004211637C1 (en) 2003-02-07 2010-08-19 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
JP4682140B2 (ja) 2003-03-05 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類縁体
EP1601685A1 (en) 2003-03-05 2005-12-07 Boehringer Ingelheim International GmbH Hepatitis c inhibiting compounds
GB0307891D0 (en) 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
EP1629000B1 (en) 2003-04-16 2009-02-18 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
SI1615613T1 (sl) 2003-04-18 2010-03-31 Enanta Pharm Inc Kinoksalinilni makrociklični inhibitorji serinske proteaze hepatitisa C
DE602004020610D1 (de) 2003-05-12 2009-05-28 Affymax Inc Neue, an den erythropoietinrezeptor bindende peptide
HRP20080014T3 (en) 2003-05-21 2008-02-29 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
EP1493440A1 (en) * 2003-07-03 2005-01-05 Rinoru Oil Mills Co., Ltd. Prophylactic agent of hypertension containing a conjugated fatty acid as an effective ingredient and the use thereof
CA2534649A1 (en) 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
UY28758A1 (es) * 2004-02-20 2005-09-30 Boehringer Ingelheim Int Inhibidores de polimerasa viral
JP5442949B2 (ja) 2004-03-08 2014-03-19 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド インドールのクロスカップリング方法
WO2005090302A2 (en) 2004-03-16 2005-09-29 Boehringer Ingelheim International Gmbh Palladium catalyzed indolization of 2-bromo or chloroanilines
UY29017A1 (es) 2004-07-16 2006-02-24 Boehringer Ingelheim Int Inhibidores de polimerasa viral
CA2597680A1 (en) 2005-02-11 2006-08-17 Boehringer Ingelheim International Gmbh Process for preparing 2,3-disubstituted indoles

Also Published As

Publication number Publication date
US8030309B2 (en) 2011-10-04
NO20064004L (no) 2006-09-06
CN101648944A (zh) 2010-02-17
KR101320907B1 (ko) 2013-10-22
RS52931B (sr) 2014-02-28
EA201301284A1 (ru) 2014-03-31
EP2626354A1 (en) 2013-08-14
EP1718608A1 (en) 2006-11-08
IL177537A (en) 2013-04-30
PL1718608T3 (pl) 2013-11-29
BRPI0507861A (pt) 2007-07-17
AU2005215829C1 (en) 2012-08-30
SG150511A1 (en) 2009-03-30
TWI368508B (en) 2012-07-21
PE20051141A1 (es) 2006-01-30
EA200901463A1 (ru) 2010-08-30
CN102911161A (zh) 2013-02-06
US20110015203A1 (en) 2011-01-20
KR20120091276A (ko) 2012-08-17
AR047706A1 (es) 2006-02-08
EP1718608B1 (en) 2013-07-17
JP5394978B2 (ja) 2014-01-22
JP2010280740A (ja) 2010-12-16
TW200539878A (en) 2005-12-16
CA2553879A1 (en) 2005-09-01
UA94602C2 (en) 2011-05-25
KR20070005635A (ko) 2007-01-10
ZA200605151B (en) 2008-04-30
CN103333162A (zh) 2013-10-02
EP1718608A4 (en) 2009-10-28
SG184700A1 (en) 2012-10-30
US7879851B2 (en) 2011-02-01
EA013207B1 (ru) 2010-04-30
JP2010195818A (ja) 2010-09-09
NZ549079A (en) 2010-08-27
ES2431314T3 (es) 2013-11-26
JP4648333B2 (ja) 2011-03-09
TWI368507B (en) 2012-07-21
AR093144A2 (es) 2015-05-20
SI1718608T1 (sl) 2013-11-29
AU2005215829A1 (en) 2005-09-01
PT1718608E (pt) 2013-08-01
CN1922174A (zh) 2007-02-28
MY144718A (en) 2011-10-31
IL219150A0 (en) 2012-06-28
HRP20130971T1 (hr) 2013-11-08
CN103319464A (zh) 2013-09-25
US20090170859A1 (en) 2009-07-02
AU2005215829B2 (en) 2012-02-09
TW201138770A (en) 2011-11-16
ECSP066780A (es) 2006-12-20
WO2005080388A1 (en) 2005-09-01
EA200601457A1 (ru) 2007-06-29
US7582770B2 (en) 2009-09-01
IL177537A0 (en) 2006-12-10
JP2007523094A (ja) 2007-08-16
JP2013237708A (ja) 2013-11-28
DK1718608T3 (da) 2013-10-14
CA2553879C (en) 2011-02-22
CN103304541A (zh) 2013-09-18
UY28758A1 (es) 2005-09-30
US20050222236A1 (en) 2005-10-06
UA86962C2 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
MY144718A (en) Viral polymerase inhibitors.
TW200617003A (en) Viral polymerase inhibitors
UA83651C2 (en) Viral polymerase inhibitors
DE602004017126D1 (de) Acylsulfonamid-verbindungen als inhibitoren der rna-abhängigen rna-polymerase
TW200626559A (en) Anilino-pyrimidine analogs
TW200724540A (en) Heterocyclic antiviral compounds
TW200716133A (en) Anti-infective agents
EA200601701A1 (ru) Ингибиторы дипептидилпептидазы
MY141255A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
GB0412769D0 (en) Organic compounds
MXPA05011962A (es) Oxiarenos substituidos.
MX2010001566A (es) Derivado de aminopirazolamida.
MXPA05013584A (es) Compuesto amina terciaria ciclica.
TW200518759A (en) Anti-infective agents
MY136824A (en) Substituted benzoxazinones and uses thereof
MX2011012541A (es) Compuestos heterociclicos antivirales.
DE60229420D1 (de) Neue metallproteinaseinhibitoren
TW200637539A (en) CTGF inhibitors
TNSN07439A1 (en) Derivatives of,4,5 - diarylpyrrole, preparation method thereof and use of same in therapeutics
TW200637870A (en) Novel pyrimidine nucleoside compound and salt thereof
TW200606163A (en) Imidazopyridine compound
IL173582A0 (en) A process for the preparation of phenyltetrazole derivatives
MX2007007554A (es) Oxiarenos sustituidos.
TW200801016A (en) Thienopyridine-2-carboxamide derivatives
TW200728301A (en) Pyrrolidine compound